MBRS-53. ENHANCED EFFICACY OF NANO-FORMULATED VISMODEGIB SHOWS THE POTENTIAL FOR POLYOXAZOLINE MICELLES TO IMPROVE DRUG DELIVERY TO BRAIN TUMORS

For the roughly 30% of medulloblastoma patients with SHH-subgroup tumors, drugs that disrupt SHH signaling offer the potential of improved efficacy with reduced toxicity compared to current, non-targeted treatment. The FDA-approved SMO inhibitor vismodegib, which targets SHH signaling at the cell me...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Hwang, Duhyeong, Zhao, Yuling, Liu, Hedi, Kabanov, Alexander, Gershon, Timothy, Sokolsky, Marina
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2018
Assuntos:
Abstracts
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6012939/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy059.498
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados